BOSTON ( TheStreet) -- Investors seeking steady dividends coupled with inflation-beating share appreciation may want to consider big drugmakers' stocks. They're expected to have as yet unrecognized growth potential from emerging market demand.Investors are discounting the potential profit contribution from emerging markets because of their recent economic volatility and investors focus on the more dominant U.S. market, while there is also a misperception that operating profit margins coming from such markets are too low to matter, wrote Damien Conover, a Morningstar drug industry analyst, in a research report. "We expect this discount will dissipate as emerging markets' economies stabilize and their sales contribution increases."
7 Big-Pharma Stocks With Untapped Potential
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.